Generics - Merck & Co

Filter

Current filters:

Merck & Co

Popular Filters

Grunenthal strengthens pain product portfolio with European rights to etoricoxib

07-05-2014

Family-owned German drugmaker Grunenthal Group today announced the signing of an exclusive promotion…

etoricoxibEuropeGenericsGrunenthalLicensingMerck & CoNeurological

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

BPH drug doesn't increase risk of death, but does save men from prostate cancer

15-08-2013

A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

Generic Temodar launches in USA

13-08-2013

Israel-headquartered Teva Pharmaceutical Industries (NYSE: TEVA) and Perrigo (NYSE: PRGO;TASE) today…

GenericsMarkets & MarketingMerck & CoNorth AmericaOncologyPerrigoTemodarTeva Pharmaceutical Industries

InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against

17-06-2013

InSite Vision (OTC BB: INSV) that it will US pharma giants join Merck & CO (NYSE: MRK) and Pfizer (NYSE:…

AzaSiteGenericsInSite VisionLegalMerck & CoMylan LaboratoriesNorth AmericaOphthalmicsPatentsPfizerPharmaceutical

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages

15-02-2013

US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Merck & Co reportedly eyeing Micro Labs buy

22-06-2012

US drugs giant Merck & Co has begun talks with privately-held Indian drugmaker Micro Labs to acquire…

GenericsMerck & CoMergers & AcquisitionsMicro LabsPharmaceutical

Cipla slashes price of generic cancer drug Nexavar in India by 76%; other cuts too

04-05-2012

Indian drugmaker Cipla (BSE: 500087) has slashed the prices of certain life-saving cancer drugs used…

Asia-PacificAstraZenecaBayerCiplaGenericsIressaMerck & CoNexavarOncologyPharmaceuticalPricingTemodar

Back to top